Using Synergistic Combination Drug Therapy to Battle Antibiotic Resistance


Edmond LaVoie, PhD, explains how his team’s approach can be applied in the development of novel drugs for the treatment of drug-resistant infections caused by Gram-negative and Gram-positive bacteria.

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, shares how his team’s research on the development of MRSA prodrug, TXA709, can help inform the development of novel drugs to treat other drug-resistant bacteria. Dr. LaVoie explains the benefits of synergistic drug combination and how this allows for fewer possibilities for resistance to develop.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.